Teva Recalls Methylphenidate Hydrochloride Extended-Release Capsules Due to Dissolution Failure
Teva Pharmaceuticals is recalling 7,579 bottles of Methylphenidate Hydrochloride Extended-Release Capsules because routine stability testing revealed out-of-specification dissolution results.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of the product could cause temporary or medically reversible adverse health consequences. The hazard is a quality control issue (dissolution failure) rather than a direct safety hazard like contamination or mislabeling of a critical allergen, and no illnesses or injuries are reported in the source text.
Plain-English summary
Teva Pharmaceuticals USA, Inc. is recalling 7,579 bottles of Methylphenidate Hydrochloride Extended-Release Capsules (LA), 40 mg, 100 count. The product is a prescription-only medication distributed nationwide. The recall is due to out-of-specification dissolution results obtained during routine stability testing.
The affected product is identified by NDC 0093-5348-01. Specific lot codes include 34010287A, 34010288A, and 34010289A with an expiration date of 4/2014, as well as 34011513A, 34011514A, and 34011515A with an expiration date of 06/14.
Consumers and healthcare providers should check their inventory for these specific lot codes and expiration dates. If the product matches the recalled description, it should be returned to the pharmacy or point of purchase for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE)
- Brand
- METHYLPHENIDATE HYDROCHLORIDE
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 7,579
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- 34010287A
- 34010288A
- 34010289A
- exp 4/2014
- 34011513A
- 34011514A
- and 34011515A
- exp 06/14.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Teva Pharmaceuticals USA, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · METHYLPHENIDATE HYDROCHLORIDE
- HighMethylphenidate Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2024-07-10
- HighMethylphenidate Hydrochloride Tablets Recalled Due to Metal Contamination
FDA (Drugs) · 2023-08-02
- ModerateMethylphenidate Hydrochloride Chewable Tablets Recalled for Failed Specifications
FDA (Drugs) · 2022-03-02
- ModerateTeva Recalls Methylphenidate Hydrochloride Extended-Release Tablets Due to Missing Desiccant
FDA (Drugs) · 2020-02-19
- ModerateTeva Recalls Methylphenidate Hydrochloride Extended-Release Tablets Due to Missing Desiccant
FDA (Drugs) · 2020-02-19
Same manufacturer · Teva Pharmaceuticals USA, Inc.
See all →- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
- ModerateTeva clonidine 0.3 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 30 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17